Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer

Jonathan A. Ledermann; Christian Marth; Mark S. Carey; Michael Birrer; David D L Bowtell; Stan Kaye; Iain McNeish; Amit Oza; Giovanni Scambia; Gordon Rustin; Frederick B. Stehman; David Gershenson; Gillian Thomas; Els Berns; Antonio Casado; Nelleke Ottevanger; Felix Hilpert; Byoung Gie Kim; Aikou Okamoto; Monica Bacon; Henry Kitchener; Gavin C E Stuart

doi:10.1097/IGC.0b013e31821b2669

Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer

Jonathan A. Ledermann, Christian Marth, Mark S. Carey, Michael Birrer, David D L Bowtell, Stan Kaye, Iain McNeish, Amit Oza, Giovanni Scambia, Gordon Rustin, Frederick B. Stehman, David Gershenson, Gillian Thomas, Els Berns, Antonio Casado, Nelleke Ottevanger, Felix Hilpert, Byoung Gie Kim, Aikou Okamoto, Monica BaconHenry Kitchener, Gavin C E Stuart

Research output: Contribution to journal › Article › peer-review

Abstract

There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference. Copyright © 2011 by IGCS and ESGO.

Original language	English
Pages (from-to)	763-770
Number of pages	7
Journal	International Journal of Gynecological Cancer
Volume	21
Issue number	4
DOIs	https://doi.org/10.1097/IGC.0b013e31821b2669
Publication status	Published - May 2011

Keywords

Clinical trials
Molecular agents
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/IGC.0b013e31821b2669

Cite this

Ledermann, J. A., Marth, C., Carey, M. S., Birrer, M., Bowtell, D. D. L., Kaye, S., McNeish, I., Oza, A., Scambia, G., Rustin, G., Stehman, F. B., Gershenson, D., Thomas, G., Berns, E., Casado, A., Ottevanger, N., Hilpert, F., Kim, B. G., Okamoto, A., ... Stuart, G. C. E. (2011). Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Gynecological Cancer, 21(4), 763-770. https://doi.org/10.1097/IGC.0b013e31821b2669

@article{19d041de953f43cdb82a66f440e75e7b,

title = "Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer",

abstract = "There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference. Copyright {\textcopyright} 2011 by IGCS and ESGO.",

keywords = "Clinical trials, Molecular agents, Ovarian cancer",

author = "Ledermann, {Jonathan A.} and Christian Marth and Carey, {Mark S.} and Michael Birrer and Bowtell, {David D L} and Stan Kaye and Iain McNeish and Amit Oza and Giovanni Scambia and Gordon Rustin and Stehman, {Frederick B.} and David Gershenson and Gillian Thomas and Els Berns and Antonio Casado and Nelleke Ottevanger and Felix Hilpert and Kim, {Byoung Gie} and Aikou Okamoto and Monica Bacon and Henry Kitchener and Stuart, {Gavin C E}",

year = "2011",

month = may,

doi = "10.1097/IGC.0b013e31821b2669",

language = "English",

volume = "21",

pages = "763--770",

journal = "International Journal of Gynecological Cancer",

issn = "1525-1438",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

Ledermann, JA, Marth, C, Carey, MS, Birrer, M, Bowtell, DDL, Kaye, S, McNeish, I, Oza, A, Scambia, G, Rustin, G, Stehman, FB, Gershenson, D, Thomas, G, Berns, E, Casado, A, Ottevanger, N, Hilpert, F, Kim, BG, Okamoto, A, Bacon, M, Kitchener, H & Stuart, GCE 2011, 'Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer', International Journal of Gynecological Cancer, vol. 21, no. 4, pp. 763-770. https://doi.org/10.1097/IGC.0b013e31821b2669

TY - JOUR

T1 - Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer

AU - Ledermann, Jonathan A.

AU - Marth, Christian

AU - Carey, Mark S.

AU - Birrer, Michael

AU - Bowtell, David D L

AU - Kaye, Stan

AU - McNeish, Iain

AU - Oza, Amit

AU - Scambia, Giovanni

AU - Rustin, Gordon

AU - Stehman, Frederick B.

AU - Gershenson, David

AU - Thomas, Gillian

AU - Berns, Els

AU - Casado, Antonio

AU - Ottevanger, Nelleke

AU - Hilpert, Felix

AU - Kim, Byoung Gie

AU - Okamoto, Aikou

AU - Bacon, Monica

AU - Kitchener, Henry

AU - Stuart, Gavin C E

PY - 2011/5

Y1 - 2011/5

N2 - There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference. Copyright © 2011 by IGCS and ESGO.

AB - There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference. Copyright © 2011 by IGCS and ESGO.

KW - Clinical trials

KW - Molecular agents

KW - Ovarian cancer

U2 - 10.1097/IGC.0b013e31821b2669

DO - 10.1097/IGC.0b013e31821b2669

M3 - Article

SN - 1525-1438

VL - 21

SP - 763

EP - 770

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 4

ER -

Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this